Loss of the tumor suppressor PTEN, a negative prognostic factor in metastatic CRPC, is associated with dysregulation of the PI3K–AKT–mTOR pathway.
In a study, brachytherapy was associated with only a slight survival advantage over dose-escalated EBRT.
Data from the CCC19 registry were evaluated to uncover risk factors associated with increased 30-day mortality in patients with cancer infected with COVID-19.
In a study of men with mCRPC receiving chemotherapy and maximal androgen ablation, those who had an objective response to treatment had a significantly higher subcutaneous adipose tissue index than those who did not.
The FDA’s accelerated approval of the PARP inhibitor rucaparib brings clinical prostate oncology into the precision medicine era.
Anticancer treatment modifications resulted in posttraumatic stress among patients and their health care providers.
Castration-resistant prostate cancer correlates strongly with development of metastasis in men with PSA relapse following radical surgery for localized prostate cancer, but it occurs much sooner, and thus may provide an intermediate endpoint in clinical trials of new therapeutics.
An overall survival advantage with olaparib was particularly observed among patients with BRCA1 or BRCA2 alterations.
Compared with sunitinib alone, nivolumab plus cabozantinib therapy was associated with a 49% decreased risk for progression and 40% decreased risk for death.
Kidney microstructural features appear predictive of progressive CKD and mortality following radical nephrectomy.